Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The move shows a gap developing between Relay and Lilly in PI3Kα inhibition.
An anti-ER “Riptac” enters phase 1.
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
